The project CARDIOPATCH, co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF), is working since its beginning on an innovative therapeutic solution for patients with myocardial infarction: a stem-cell smart patch able to regenerate tissues damaged after this kind of cardiovascular disease.
In order to update the current situation of the initiative, the partners of its consortium gathered together virtually on the 17th of June at the fourth scientific meeting. Each partner reported on the progress made the last months in the Work Packages that are working on and showed which are the next steps to be made.
The first speaker was the researcher Marta Costa from the partner IBET and she explained their work in the WP3, which consists on the development of technologies and protocols for standardized production and characterization of the different types of therapy products for cardiac regenerative medicine that are being designed in CARDIOPATCH. She showed how their team is optimising a bioprocess for production and purification of genetically modified ADCS (adipose tissue-derived stromal cells).
After that, CHUT’s expert Anne-Catherine Prats reported the main results obtained in the last months on the increase of the therapeutic cardioprotective and pro-angiogenic potential of ADSC through gene therapy. She also mentioned the next steps to be taken, including the delivery of new samples to the IBET partner.
In addition, Mariana Almeida from the partner GENIBET presented the advances made on the evaluation of the readiness and compliance of the protocols used for cell growth as part of their work in the WP4: Evaluation of the ATMP compliance of the developed protocols.
Following that, Coline Pinese, from the partner IBMM, intervened to give an update on their work in the WP5 and how they are functionalizing the collagen membrane of the patch with protein factors involved in cardioprotection and angiogenesis.
Then, Dr. Beatriz Pelacho, scientific coordinator of the project, represented the partners FIMA and CUN to analyze the advances made on the Work Packages 6 and 7 and how will be determined the therapeutic potential of the cellularized and functionalized patches in a porcine preclinical model of myocardial infarction.
Finally, the researchers Uzuri Urtaza and Mikel Garmendia, from Leartiker, discussed the progress done in the WP8 and 9: the development of a new rolling collagen scaffolds for heart implantation by mini-thoracotomy and the creation of a 3D system for the culture and transport of the cellularized patch.
Led by Clínica Universidad de Navarra (CUN), CARDIOPATCH includes partners from Spain, France and Portugal: CIMA Universidad de Navarra, via the Foundation for Applied Medical Research, Leartiker Technology Center, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, communication agency GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) - Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and the Instituto de Biologia Experimental e Tecnológica.